Candidemia is the fourth most common kind of microbial bloodstream infection, with
F
ungal infections have emerged over the last few decades as a consequence of increasing cohorts of at-risk individuals. Candida albicans is the most important opportunistic fungal pathogen in humans (1) . Mortality rates from C. albicans infection are estimated to be as high as 45% (2) , partly due to delayed or inaccurate diagnosis and inappropriate antifungal therapies.
Echinocandin drugs are recommended as the first-line treatment for invasive candidemia (3, 4) . Anidulafungin (ANI), caspofungin (CAS), and micafungin (MICA) are lipopeptidic antifungal agents that inhibit the synthesis of the fungal wall component ␤-(1,3)-D-glucan by noncompetitively blocking the ␤-(1,3)-Dglucan synthase. Drug resistance is emerging in patients with C. albicans, C. glabrata, C. tropicalis, and C. krusei infections (5-7), which complicates disease monitoring and patient management (8) . Presently, echinocandin resistance in C. albicans occurs with an incidence of Ͻ1% (9) . Single-residue substitutions located in two hot spot regions in each of the genes FKS1 and FKS2 (10), but not FKS3, have been associated with elevated echinocandin MICs (11) in Candida species.
So far in C. albicans, only amino acid substitutions within FKS1 encoding the ␤-(1,3)-D-glucan synthase complex were found in echinocandin-resistant isolates (12) . The most frequent amino acid changes reported were at positions F641, L644, S645, R647, D648, P649 (10), W1358, and R1361 (13) within hot spot 1 (HS1) (amino acid positions 641 to 649, FLTLSLRDP) (12) and hot spot 2 (HS2) (amino acid positions 1357 to 1364, DWIRRYTL) (14) , respectively. HS1 and HS2 alterations leading to changes in F641, S645, and R1361 were associated with pronounced MIC elevations. Other HS mutations (in L644, R647, D648, P649, and W1358) confer a discrete MIC increase (14) . C. albicans is a diploid fungus carrying a pair of each chromosome and at least two alleles of each gene locus (15) . An amino acid substitution in one allele (heterozygous) affects only half of the total cellular glucan synthase pool that can be targeted by echinocandins (5) , while substitutions occurring in both alleles (homozygous) affect the whole glucan synthase pool.
Here, we identify and report the first in vivo-selected HS1 FKS1 double mutation (R647R/G and P649P/L) in one allele in C. albicans after long-term caspofungin (CAS) therapy (including a detailed case report and therapeutic regimes). The treatment response of a clinical wild-type (WT) strain and the corresponding sequential heterozygous derivative mutants (R647R/G and P649P/L) are compared using a well-validated murine model of disseminated candidiasis. ANI, CAS, or MICA was applied at a standard dose (designated as AUC 100 , where AUC is the area under the concentration-time curve) or elevated dose (AUC 500 [five times the standard dose]) and compared with each other and the placebo control group.
The impacts of heterozygous single (R647R/G or P649P/L) and double mutations (R647R/G and P649P/L), as well as homozygous double mutations (R647G and P649L), in FKS1 on virulence and in vitro and in vivo susceptibilities were tested in isogenic (identical genetic background) mutant strains.
The hypothesis addressed in this study was that heterozygous double mutations, as well as homozygous double mutations within one allele, enhance the in vivo therapeutic resistance of C. albicans strains even with a dose escalation. We were able to (i) confirm this hypothesis, (ii) show significant differences in the activities of the three echinocandins, and (iii) demonstrate that the reported single nucleotide polymorphisms (SNPs) have no impact on virulence.
MATERIALS AND METHODS
P649P/L), RS MH1 (R647R/G), SR MH1 (P649P/L), and RR MHO2 (R647G and P649L), according to EUCAST methodology (EDEF 7.2) (21) (see Table 1 ). In addition, CAS and amphotericin B were tested using CLSI methodology and Etest (bioMérieux). C. krusei strain ATCC 6258 or Candida parapsilosis strain ATCC 22019 (21, 22) was used as a quality-control strain.
Sequencing of FKS1 gene regions hot spot 1 and hot spot 2. Genomic DNA was extracted using the UltraClean microbial DNA isolation kit (Mo Bio Laboratories, Inc.), according to the manufacturer's instructions. Sequencing was performed using the same primers and conditions as those published by Garcia-Effron et al. (23) . In short, the Candida universal FKS1 primers 1HS1F (AAT GGG CTG GTG CTC AAC AT) and 1HS1F (CCT TCA ATT TCA GAT GGA ACT TGA TG) were used for amplifying FKS1 HS1, while for FKS1 HS2, the primers 1HS2F (AAG ATT GGT GCT GGT ATG GG) and 1HS2R (TAA TGG TGC TTG CCA ATG AG) were used. As a PCR master mix, the Qiagen LongRange PCR kit and conditions were as follows: initial denaturation at 96°C for 4 min, followed by 40 cycles of 94°C for 30 s, 55°for 30 s, 74°C for 90 s, and a final elongation step of 74°C for 4 min. For cleaning the PCR products, ExoSAP-IT was used. For sequencing, the BigDye Terminator version 3.1 cycle sequencing kit was used in combination with the 3500 Genetic Analyzer (Applied Biosystems), according to the manufacturer's instructions. Construction of isogenic C. albicans FKS1 mutants. The generated isogenic mutant plasmids used are shown in Table S1 in the supplemental material, and the primers used are shown in Table S2 in the supplemental material. An FKS1 deletion cassette was constructed using the SAT1 flipper technology (24) with the primers FKS1_55 and FKS1KO_53 for the upstream homologous region and FKS1_35 and FKS1_33 for the downstream homologous region. The homologous regions were cloned into pSFS2a (24) using the restriction sites ApaI/XhoI and SacII/SacI, respectively. The resulting plasmid was linearized with PvuI and transformed into C. albicans SC5314 (25) to replace the FKS1 coding sequence and get a heterozygous FKS1/fks1 knockout (see Table S3 in the supplemental material). The SAT1 marker was recycled by overnight cultivation in maltose-containing medium.
For reintegration of the FKS1 gene at its endogenous locus, the FKS1 coding sequence was cloned into pSFS2a-FKS1dr (pSFS2a containing the downstream homologous region of the deletion cassette) with the primers FKS1_55 and FKS1clo_53 and using the restriction sites ApaI/XhoI. The resulting plasmid (pSFS2a-FKS1reint) was linearized with PvuI and transformed into C. albicans strain CA-MT424 (FKS1/fks1). Correct integration was checked by colony PCR.
For the mutagenesis of FKS1, PCRs were performed using pSFS2a-FKS1reint with the primers FKS1_55 and the corresponding mutagenesis reverse primer, as well as with the corresponding mutagenesis forward primer and FKS1_33, respectively (see Table S3 in the supplemental material). The purified PCR products were mixed, and the whole reintegration cassette was amplified using the primers FKS1_55_2 and FKS1_33_2. The cassette was transformed into CA-MT424 to integrate the mutated FKS1 allele at the deleted locus. Correct integration was checked by colony PCR, and the SAT1 marker was recycled.
For the construction of homozygous mutants, the PCRs were performed with primers FKS1_55 and the corresponding mutagenesis reverse primer, as well as with the corresponding mutagenesis forward primer and FKS1clo_53, respectively. The purified PCR products were mixed, the mutated FKS1 coding sequence was amplified using the primers FKS1_55 and FKS1clo_53; this was cloned into pSFS2a-FKS1dr as described above for the reintegration plasmid. Prior to transformation, the plasmids were linearized with PvuI. For the construction of the homozygous double mutant, pSFS2a-FKS1_2mut_reint was used to replace the wild-type allele in C. albicans strain CA-MT441 (see Table S2 in the supplemental material). Correct integration was checked by colony PCR, and the SAT1 marker was recycled. For the construction of the homozygous single mutants, the corresponding plasmids containing mutated FKS1 alleles were used for integration at the deleted alleles of C. albicans strains CA-MT457 and CA-MT458, respectively. In these two strains, the wild-type allele in CA-MT424 had been directly replaced before by the corresponding mutated allele. The presence of the introduced point mutations was confirmed by sequencing the corresponding region in all mutants.
Hematogenous mouse model. (i) Pilot study for inoculum determination. To evaluate the in vivo virulence of isogenic mutant strains, a total of 24 NRMI mice were challenged in groups of three with four isogenic mutant strains (C. albicans SS MH2 , RS MH1 , SR MH1 , and SS MHO2; detailed information is shown in Table 1 ; see also Table S1 in the supplemental material) and two inoculum amounts (5 ϫ 10 5 CFU/mouse and 5 ϫ 10 6 /mouse). The aim was to achieve sufficient infection without causing mortality. Using a C. albicans cell concentration for infection of 5 ϫ 10 6 / mouse, nine out of 12 mice died. Challenging the mice with a dose of 5 ϫ 10 5 CFU/mouse led to one out of three mice per group dying, and the kidney burden in the surviving mice was found to be between 10 4 and 10 5 CFU/ml kidney homogenate. Hence, an inoculum of 1 ϫ 10 5 /mouse was used for the treatment studies.
(ii) In vivo treatment studies. Evaluation of in vivo resistances of C. albicans clinical isolates (S CL and RR CL strains; Tables 1 and 2) against ANI, CAS, MICA, and the placebo (0.09% NaCl) was performed in a hematogenous mouse model. Eighty-four NMRI mice (weight, 26.0 g to 30.0 g; Harlan Scandinavia, Allerød, Denmark) were kept with free access to food and water. On day 0, the mice were challenged by intravenous injection (200 l administered with a 25-gauge syringe) of a C. albicans (5 ϫ 10 5 CFU/ml; final concentration per mouse, 1 ϫ 10 5 ) suspension. The mice were challenged with either of the two strains S CL (n ϭ 42 mice) or RR CL (n ϭ 42 mice) and treated by the intraperitoneal (i.p.) route on days 1 to 3 with 0.5 ml of either ANI, CAS, or MICA at standard (AUC 100 ) and high-dose (AUC 500 ) or with a placebo (see below).
The treatment studies of isogenic mutant strains and their parental strain were divided into three animal experiments (per antifungal compound tested), as a total of 312 NMRI mice (weight between 26.0 g and 30.0 g) were used. The inoculation of mice and treatment scheme were performed as outlined above, and the dosing was as described below. The treatment groups consisted of six mice and control groups of eight mice. As a backup, four additional mice were available to replace mice that were inoculated outside the tail vein and therefore excluded; if the backup mice were not needed, they were allocated to the control groups (hence, some control groups included nine mice).
The echinocandin treatment doses used in the murine model were the standard dose (AUC 100 ), which was the dose that resulted in human equivalent exposure and was calculated using our echinocandin pharmacokinetic-pharmacodynamic studies in this exact mouse model reported previously (26) , ANI 100 (2.16 mg/kg of body weight), CAS 100 (0.76 mg/ kg), and MICA 100 (2.71 mg/kg). The high dose (AUC 500 ) was five times the human-equivalent exposure dose and was included in order to examine if a dose escalation would be useful for overcoming the resistance of C. albicans.
For determining the fungal burden (CFU/ml tissue homogenate), kidneys were aseptically removed at day 4. The organ weights were determined, and the kidneys were placed in sterile physiological saline (750 l per pair of kidneys); the organs were stored at Ϫ80°C prior to counting CFU. The fungal burden was determined using the spot technique, which involved plating two 20-l spots of 10-fold dilutions of tissue homogenate (homogenization performed with a homogenizer [RW 16 Basic; IKA Labortechnik, Bie & Berntsen, Copenhagen, Denmark]). The CFU count was expressed as the log 10 of CFU/ml kidney homogenate. The lower limit of detectable CFU was 25 CFU/ml tissue homogenate. All murine experiments reported in this study were approved by the Danish Animal Experimentation Committee under the Ministry of Justice (2009/561-1637).
Statistical analyses. To check for normal distribution of the fungal burden data, the Shapiro-Wilk normality test was performed. The Kruskal-Wallis test was then applied, as the data were found to be not normally distributed. Outliers (maximum one per control group with Ͻ100 CFU/ml kidney homogenate) in the control groups (each eight placebo-treated mice) were removed for statistical significance calculation, as these mice did not successfully establish a manifest C. albicans infection or clear the infection. The outliers were identified by Prism GraphPad version 5. To guarantee the transparency of all data and to provide the readers with a complete image, the outliers are included in all tables and figures. In all analyses, P values of Յ0.05 were regarded as statistically significant.
Filamentation ability tests. All studied C. albicans strains were grown overnight on Sabouraud 2% glucose agar (Carl-Roth) at 37°C. The cells were harvested in 0.9% NaCl. The cell number was adjusted to 5 ϫ 10 5 cells/ml using the Neubauer CE chamber hemocytometer. A volume of 500 l was centrifuged at 13,000 rpm for 5 min in a Mikro 20 (Hettrich) centrifuge, the supernatant was discarded, and the cell pellet was suspended in 500 l fetal bovine serum (FBS) (Gibco, Invitrogen). FBS with cells was transferred into a Nikon BioStation IM (Nikon) cell incubator and monitoring system. The cells were evaluated by microscopy after 0.5 h, 1 h, 2 h, and 3 h incubation at 37°C in the Nikon BioStation IM using BioStation software version 2.1. In addition, for a long-time (4 h) comparison of the germ tube formation experiment, movies were captured for SC5314, RR MH2 , S CL , and RR CL in four individual experiments per strain. The images were captured every 10 min at ϫ200 and ϫ400 magnification.
Chitin content measurement by FACS analyses. All studied C. albicans strains were overnight grown on Sabouraud 2% glucose agar at 37°C. The cells were harvested in 0.9% NaCl. The cell number was adjusted to 5 ϫ 10 6 cells/ml using the Neubauer CE chamber hemocytometer. The cells were inoculated into fresh Sabouraud 2% glucose agar and were harvested after 4 h of incubation at 37°C with shaking at 200 rpm. The samples were fixed in 10% (vol/vol) neutral-buffered formalin for 15 min. The cells were washed with sterile 0.9% NaCl and stained with 25 g/ml calcofluor white (Sigma-Aldrich) for 15 min at room temperature. The cells were washed twice with 0.9% NaCl to remove excessive stain, and they were filtered using a CellTrics filter (5 m pore size; Partec) to remove cell clumps. The cells were prepared using the standard procedure for fluorescence-activated cell sorter (FACS) analysis. The measurement of 10,000 events was carried out using the FACSVerse flow cytometer (BD Biosciences). The results were given as the fluorescence intensity (calcofluor-A). Unstained SS WT (SC5314) was used as the reference strain for gaiting the cell population. For statistical analyses, the minimum, median, and maximal fluorescence signals were determined. SS WT stained with calcofluor white served as a wild-type reference. The fluorescence peaks of the clinical isolates (strains S CL and RR CL ) were compared to the fluorescence peak of the SS WT population. All FACS experiments were performed independently in triplicate. 
RESULTS

In vivo
a Nucleic acid mutation. Boxheads indicate position (wild-type nucleic acid). b Regular type, amino acid change: nucleic acid change does not result in a change of amino acid (regular type); bold type, wild-type amino acid/position/heterozygous mutation. c Amino acid change, arginine (R) to glycine (G); codon change, AGA to GGA. d Amino acid change, proline (P) to leucine (L); codon change, CCU to CUU.
against ANI, CAS, MICA, fluconazole (FLU), isavuconazole, voriconazole (VOR), and amphotericin B. The isolates from 2004 were found to be FLU and VOR resistant but echinocandin susceptible according to the EUCAST breakpoints (using ANI as a marker for ANI and CAS susceptibility, as is currently recommended) and CAS susceptible according to the CLSI breakpoints (22, 27) . In contrast, the isolates gained in 2012 were micafungin resistant and showed an elevated ANI MIC compared to that of the initial isolate but not exceeding the EUCAST breakpoint (MIC, 0.03 mg/liter; ANI breakpoint, susceptible [S] Յ 0.03 mg/ liter); they were therefore classified as anidulafungin and caspofungin susceptible using the EUCAST breakpoint, with anidulafungin as a marker for caspofungin. In contrast, these isolates were classified as caspofungin resistant using the Etest and CLSI breakpoints. Detailed data on the MICs are given in Table 1 .
To investigate the underlying molecular resistance mechanism, FKS1 HS1 and HS2 were sequenced. Notably, strains isolated in 2004 carried four silent mutations (no amino acid [aa] change, also called synonymous substitution), one within the FKS1 HS1 A1929T (T643) and five outside the FKS1 HS regions, located at nucleic acid positions A1641A/T (P547), A1653A/G (T551), T1662T/C (I554), C4125C/T (I1375), and T4230T/C (A1410). In addition, two missense (i.e., having an aa change, also called nonsynonymous) mutations in the same allele (heterozygous) were found at nucleic acid positions A1939A/G and C1946C/T, leading to the residue changes R647R/G and P649P/L, respectively (Table 2) . Identical silent mutations found in FKS1 HS1 and HS2 were shared by all isolates, strongly suggesting their clonal origin and in vivo development of resistance. To verify this hypothesis, randomly amplified polymorphic DNA typing (RAPD typing) was performed with five markers (M13, CA2, OPA18, OPE18, and RSD10). As displayed in Fig. 2 , the RAPD genotype was identical for the clinical isolates. The data herein support the development of acquired CAS resistance in C. albicans during a 6-year treatment period with CAS.
To evaluate the impact of the double mutations on the therapeutic response in vivo, the in vitro echinocandin-resistant clinical isolate carrying the R647R/G and P649P/L mutations (RR CL ) and the susceptible wild-type clinical isolate (S CL ) were compared in a murine hematogenous candidiasis model. ANI, CAS, and MICA were administered at two doses (AUC 100 and AUC 500 ). The fungal burden in the kidney homogenates of animals infected with the susceptible wild-type strain were significantly reduced (Fig. 3) . Comparing the control mouse group with each of the treatment groups, the reduction in kidney burden was found to be highly significant in all treated groups (P Ͻ 0.01), with the exception of that for MICA 100 , for which the reduction was less pronounced, albeit still statistically significant (P Ͻ 0.05) (see Table S4 in the supplemental material).
In contrast, the reduction in kidney burden failed to reach statistical significance (between the different treatment groups and between the placebo with the treatment groups) in mice infected with RR CL (MICs of Յ0.03 g/ml [ANI], Ͼ1 g/ml [MICA], and Ͼ2 g/ml [CAS]). By comparing the median values of different treatments with those of the placebo groups, it is obvious that the fungal burden is lowest in ANI 500 and CAS 500 , followed by ANI 100 and CAS 100 and the placebo control (see Table S5 in the supplemental material). Significant differences in the CFU/g kidney within the control groups of mice infected with either S CL or RR CL were observed, as well as differences between those receiving standard and high-dose medications (see Table S4 in the supplemental material). By comparing the median values of S CL (MICs of Յ0.008 g/ml [ANI and MICA] and 0.125 g/ml [CAS]) and RR CL , a reduction in that for RR CL is obvious even if not statistically significant ( Fig. 3 ; see also Table S5 in the supplemental material). These in vivo data fully support and correlate with the in vitro data, as ANI was found to be the most active echinocandin against RR CL in vivo.
Influence of heterozygous single and double mutations and homozygous double mutations on virulence and in vivo treatment response. To evaluate the influence of both mutations individually and in combination, both in vitro and in vivo, isogenic mutants (identical genetic background) were generated (see Table  S1 in the supplemental material). An overview of the in vitro susceptibility results of the parental strain and isogenic mutants is given in Table 1 . The parental strain and SR MH1 (heterozygous P649P/L) were classified as susceptible in vitro against all echinocandins. RS MH1 (heterozygous R647R/G) was classified as resistant to MICA only, since it was only one dilution step above the breakpoint. Strain RR MH2 (heterozygous double mutation; P649P/L and R647R/G) and RR MHO2 (homozygous double mutation; P649L and R647G) were classified as panechinocandin resistant in vitro. Notably, the ANI and MICA MICs were only one dilution above the respective breakpoints for the heterozygous double mutant RR MH2 . But the homozygous double mutant RR MHO2 had a MICA MIC that was six dilutions above the breakpoint. Thus, a stepwise increase in MICs and development from single-echinocandin to multiple-echinocandin resistance was observed comparing single to double codon alterations and heteroto homozygous mutations, respectively. Comparing the clinical heterozygous double mutant RR CL with the heterozygous isogenic mutant RR MH2 , it is obvious that these two mutations apparently affect ANI susceptibility to a much lesser extent than they affect susceptibility to MICA and CAS, as the MICs for MICA and CAS were several times higher. However, caspofungin testing was performed using the commercial Etest and therefore may not be directly comparable (28) , and an interpretation of the MICA susceptibility data should be done with caution, as both isolates showed a trailing phenotype, the implication of which has not been elucidated for the echinocandins (Table 1) .
To evaluate the differences in the in vitro responses toward the different echinocandins in vivo, a murine model was again used (Fig. 4) . A statistically significant reduction in the fungal burdens in kidneys was observed for ANI, CAS, and MICA (AUC 100 and AUC 500 ) and mutant strains compared to those of the placebotreated controls. The median of fungal burden per treatment arm and placebo group prove that the parental strain (SS WT ) and the two strains carrying a heterozygous single mutation have the best in vivo treatment responses (see Table S6 in the supplemental material). This is in agreement with in vitro data, as all strains were categorized as ANI susceptible (Table 1) . Dose escalation markedly reduced the fungal burden of the heterozygous double mutant RR MH2 , whereas the burden reduction for the homozygous double mutant RR MHO2 was less prominent (see Table S6 ). All CAS-treated groups showed statistically significant lower fungal burdens than the mice in the placebo control groups. By comparing the median fungal burden, the treatment efficacy against the heterozygous double mutant RR MH2 was limited at the standard dose but improved with dose escalation (see Table S6 ). While in vitro resistance to CAS was confirmed in vivo for the RR MH2 mutant, resistance in RR MHO2 was not observed in vivo. Based on their fungal burdens, SS WT , RS MH1 , and SR MH1 were found to be CAS susceptible both in vivo and in vitro (Table 1 and Fig. 4) .
The micafungin-treated groups displayed statistically significant lower fungal burdens than those of the placebo-treated mice (P Ͻ 0.05; see Fig. 4 ). The two double mutants RR MH2 and RR MHO2 showed only limited responses against MICA 100 treatment. In contrast to RR MHO2 , RR MH2 responded to dose escalation. Both strains were resistant toward MICA in vitro. For all other strains, standard dosing was sufficient to clear the infections (Fig. 4) , even though RS MH1 was found to be MICA resistant according to the EUCAST breakpoints (Table 1) . However, we would like to mention that the clinical isolates and the mutants constructed in the laboratory represent different background strains, and therefore, comparisons have to be made with caution.
The clinical isolates (S CL and RR CL ) were found to differ in virulence in terms of kidney CFU count and treatment responses (Fig. 3) . On the contrary, isogenic mutants that exclusively carry FKS1 HS1 mutations did not vary in their virulence (Fig. 4) . The major difference between RR MH2 and RR CL was that RR MH2 responded to dose escalation of ANI, CAS, and MICA, whereas RR CL did not. Thus, a clear trend between standard and escalated dosing was found for RR MH2 and RR MHO2 and ANI and MICA ( Fig. 4 ; see also Table S5 in the supplemental material). In contrast to the clinical isolates, no differences in virulence were observed in a comparison of the parental strain and the isogenic mutants ( Fig.  4 ; see also Table S6 in the supplemental material).
Fluorescence-activated cell sorting (FACS) analyses on the chitin content of clinical isolates (S CL and RR CL ), isogenic mutants (SR MH2 , RS MH2 , RR MH2 , and RR MHO2 ), and SS WT (used as a reference) resulted in highly similar fluorescence signals for all cell populations (see Fig. S1 and S2 in the supplemental material). In vitro germination tests in fetal bovine serum showed that both clinical isolates S CL and RR CL showed decreased filamentation efficacy. After 1 h at 37°C, about 60% of all cells formed germ tubes, while all isogenic mutants (RS MH1 , SR MH1 , RR MH2 , and RR MHO2 ) behaved like the parental wildtype strain SC5314 (after 1 h at 37°C, 100% of all cells formed germ tubes) (Fig. 5) . A decreased filamentation ability was most pronounced in RR CL .
For the first time, it was demonstrated that these SNPs in FKS1 HS1 do not necessarily have an impact on the (i) chitin content, (ii) filamentation ability, and (iii) virulence of C. albicans strains when only these SNPs are integrated into a wild-type strain.
DISCUSSION
In the current study, a female patient suffering from CMC due to MICA-and CAS-resistant C. albicans (Table 1) failed to be cured by long-term CAS medication but was cured by ANI. To determine whether strain RR CL evolved from S CL or replaced S CL under selection pressure of CAS, RAPD genotyping of the clinical isolates was performed. The efficacy of RAPD as a typing method for clinical C. albicans isolates was previously demonstrated (17, 18) . RAPD revealed a clonal relationship between the isolates (Fig. 2) , which was additionally supported by the presence of six identical synonymous substitutions, one of which was located in the FKS1 HS1 (Table 2 ). Based on this data, we conclude that echinocandin resistance of C. albicans emerged in the patient.
Molecular analyses demonstrated that RR CL carried the amino acid substitutions R647R/G and P649P/L in FKS1 HS1 in the same allele (Table 2) ; the occurrence of such a double amino acid substitution in FKS1 HS1 is new, and its impact on in vitro and in vivo echinocandin susceptibility is demonstrated for the first time.
Recently, it was shown that isolated heterozygous (29) and homozygous (23) point mutations at the amino acid position P649 refer to echinocandin resistance. In contrast to the isolates studied by Arendrup et al. (29) and Garcia-Effron et al. (23) , our clinical isolate carries a heterozygous P649P/L substitution that is accompanied by a second amino acid substitution (R647R/G). Also, the isolated homozygous amino acid substitution R647G was published previously by Dannaoui et al. (30) . This mutation was found to influence the MICs of only CAS and MICA but not ANI. In general, mutations at positions P649 and P647 in C. albicans were associated with discrete elevations of echinocandin MICs compared with those of FKS1 HS1 alterations involving codons S645 and F641 (22) . In our study, only the simultaneous presence of both mutations leads to high-level MICs for CAS and MICA (Table 1) . Infections caused by isolates carrying an FKS1 mutation at either position S645 or F641 were not cleared by standard doses (10 mg/kg) of MICA and CAS (31, 32) . This is similar to our data, as strain RR CL was demonstrated in vivo to be resistant in a hematogenous murine model against all echinocandins at a standard dose (Fig. 3) . However, in our case study, CMC was cured successfully with ANI treatment. This discrepancy may be explained by various factors. First, the hematogenous infection in the animal model may be more difficult to cure than the lesssevere superficial infection in this patient. Second, the lower virulence and growth rate of the clinical isolate may lead to a slower response to treatment, as a certain number of multiplication rounds are needed for activity. Thus, efficacy might have been obtained if the treatment duration had been extended beyond the standard 3 days in the mouse model. Moreover, comparing the in vitro susceptibility of RR CL with that of the corresponding isogenic mutant strain RR MH2 , it is obvious that ANI susceptibility is less influenced by these mutations than is the case for CAS and MICA. The MICs of the clinical isolate are remarkably higher for CAS and MICA. This finding correlated with the clinical response, as the patient failed caspofungin but not anidulafungin treatment. Since strain RR MH2 displays pronounced trailing when tested according to the EUCAST breakpoints, however, the micafungin MIC data interpretation may be affected.
A fundamental finding was that the clinical isolate RR CL and the corresponding RR MH2 differ in their in vivo responses, particularly with dose escalation (AUC 500 ) ( Fig. 3 and 4) . The efficacy in mice challenged with RR CL was not improved with high doses of ANI, MICA, and CAS, in contrast to what was observed for mice challenged with the isogenic mutant RR MH2 . Such differences may be explained by the different genetic backgrounds of the clinical and the laboratory-derived mutant strains or by additional molecular mechanisms that were acquired by RR CL during long-term exposure to CAS. Such additional adaptations associated with echinocandin resistance in C. albicans were published previously; among them are the overexpression of HSP90 (33), the overexpression of Cdr2p ATP-binding cassette (ABC) transporter (34) , and elevated chitin levels in fungal cell wall (35) . Besides the FKS1 HS1 mutations, additional simultaneously operating mechanisms might contribute to the altered echinocandin resistance of the clinical C. albicans strain RR CL . To fully address the question of alternative mechanisms that enhance echinocandin resistance, a whole-genome comparison and RNA sequencing will be performed on the clinical isolates S CL and RR CL . Interestingly, others have reported that some FKS1 mutations are associated with reduced virulence and fitness in clinical and laboratory-derived mutant strains (35) (36) (37) . In the current study, the fungal loads of tissue homogenates of mice infected with either the parental strain SC5314 or isogenic mutant strains were identical, suggesting that mutations do not affect virulence or fitness in vivo. Notably, the clinical isolates S CL and RR CL show reduced filamentation in vitro, in contrast to those of the parental strain SC5314 and the derived isogenic mutants ( Fig. 1 and 5 ). Ben-Ami et al. (36) explained the loss of fitness in homozygous FKS1 HS mutants (F641S, S645F, and S645P) by a reduced maximum catalytic capacity of glucan synthase complex and increased cell wall chitin that comes along with thickened cell walls hampered by filamentation capacities (37) . The isogenic mutants investigated herein (carrying either R647R/G and/or P649P/L or R649G and P649L in FKS1 HS1) lacked any change in cell wall chitin (see Fig.  S1 in the supplemental material). Therefore, mutations at positions R647R/G and/or P649P/L seem not to influence the filamentation of C. albicans, adding to the previous observations that various resistance mutations may or may not influence virulence and fitness (38) . The impact of the position of the amino acid substitution in the FKS1 gene on the fitness of C. albicans needs to be further investigated using competition experiments with barcoded strains. Moreover, increased or decreased fitness of organisms may depend on the immune status of the host, as significant differences between immunocompetent and neutropenic mice were found (37).
Slater et al. (31) reported that infections due to homozygous FKS S645 mutants were not cleared with MICA at standard or elevated (AUC 400 ) doses. The finding of Slater et al. (31) might be explained by the fact that S645 is the most dominant resistance mutation described yet, and in comparison to our study dose, it was escalated only four times. In our study, infections with RR MHO2 failed treatment with MICA 100 , ANI 100 , CAS 100 , MICA 500 , and ANI 500 (Fig. 4) , even though a dose response was observed, as the CFU count decreased for escalated doses (AUC 500 ). Compared with strains in the study of Slater et al. (31) , our strains carry weaker mutations and therefore show a partial dose-dependent response. However, only CAS 500 was able to clear the infection with RR MHO2 below the detection level. Hence, dose escalation may not be sufficient to fully overcome infections with double-mutant strains.
Translated into clinical practice, our data suggest that the EUCAST MICs of echinocandins interpreted by the associated EUCAST breakpoints correlate with in vivo responses using a standard dosing regimen, but they cannot predict the in vivo response to dose escalation according to the murine model applied. Of note, EUCAST and CLSI have abstained from setting caspofungin epidemiological cutoff values for Candida species because of unacceptable high variation in the MIC ranges obtained over time and between centers (27) . Also, commercial systems, such as Etest, do not overcome these variation problems (28) . Therefore, it is currently not recommended to perform caspofungin susceptibility testing in routine laboratories; instead, anidulafungin and micafungin should be tested and reported as echinocandin markers (27) . Nevertheless, caspofungin susceptibility testing is performed for research purposes to evaluate the degree of increase in the MIC. The presence of simultaneous mutations within the FKS1, as well as the history of long-term echinocandin therapy and the occurrence of homozygous FKS1 mutations, should be treated with caution in terms of ongoing treatment with ANI, CAS, or MICA. The presence of an FKS1 HS mutation in a clinical isolate does not necessarily imply that the isolate is less virulent than a wild-type C. albicans strain. C. albicans strains carrying either a heterozygous/homozygous double mutation in an allele or homozygous single mutations are more likely to be therapy refractory in vivo not only at standard doses but also with dose escalation.
In conclusion, the adoption of EUCAST breakpoints for the clinical strains resulted in a classification that correlated with the clinical response in the patient. In the animal model, the clinical strains with heterozygous double mutations within the FKS1 gene and the laboratory-generated strain with a homozygous double mutation failed to respond to dose escalation. C. albicans strains carrying heterozygous double mutations have higher in vitro MICs for echinocandins than do the parental and heterozygous single-mutation strains. Neither the heterozygous single mutations (R647R/G and P649P/L), the heterozygous double mutations (R647R/G and P649P/L), nor the homozygous double mutations (R647G and P649L) in the FKS1 HS1 had an impact on (i) the virulence of isogenic C. albicans with respect to CFU/ml kidney homogenate, (ii) the filamentation capacity, and (iii) chitin content. Therefore, any loss of fitness and/or virulence cannot be provided based on the presence of FKS1 HS mutations, but it probably depends on the nature and position of the specific alteration. The various FKS1 HS mutations differ in MIC elevations, in their response to ANI, CAS, and MICA, and in their impact on virulence.
